ViiV Healthcare is an independent company 100% focused on the needs of people living with HIV

• Their aim is to take a deeper and broader interest in HIV/AIDS than any company has done before
• ViiV Healthcare was established in November 2009, combining the power and expertise in the management of HIV from both GSK and Pfizer. Shionogi joined ViiV Healthcare in 2012.
• Their portfolio is built on 10 available medicines that generate annual sales of more than £1.5 billion, providing us with financial stability, investment capital and enabling us to take a sustainable, long-term view
• They have an industry-leading pipeline of six innovative and targeted compounds in development
• They are committed to develop further fixed dose combinations of antiretroviral drugs that will meet the needs of specific groups of HIV-positive people
• They support fresh approaches to improve access to HIV treatments
• ViiV Healthcare supports sustainable community projects making a difference at grassroots level in over 46 countries

Their ethos 

HIV presents a serious global challenge. At ViiV Healthcare, we are using our commitment, expertise and passion to help meet this challenge. Their entrepreneurial attitude encourages us to be nimble and agile, so they can respond rapidly to changing healthcare and social needs for people living with HIV.

Their strategy

Their aim is to re-energise the pharmaceutical industry’s participation in HIV by getting closer to and understanding better the needs of those who live with the virus and those who treat them.

They have three strategic priorities:

Innovation in research and development (R&D) - ViiV Healthcare is structured to provide a more consistent flow of new medicines. They do this by tapping into the R&D expertise of not 1 but 2 drug discovery pipelines and actively seeking new business alliances.

Delivering a business today, that is built for the long term - Their operating model allows us to make business decisions fast. They also have a broad portfolio of available medicines. This makes us a robust company and enables us to take a long-term view

Access and care - Their royalty-free voluntary licence scheme and not-for-profit pricing underpin our commitment to supporting global access for people needing antiretroviral drugs. In addition, they actively support community initiatives in HIV, including the Positive Action programme, by partnering with like-minded organisations that share their ethos.